Gross Profit Analysis: Comparing Teva Pharmaceutical Industries Limited and Perrigo Company plc

Teva vs. Perrigo: A Decade of Gross Profit Trends

__timestampPerrigo Company plcTeva Pharmaceutical Industries Limited
Wednesday, January 1, 2014144770000011056000000
Thursday, January 1, 2015171240000011356000000
Friday, January 1, 2016205180000011859000000
Sunday, January 1, 2017197950000010825000000
Monday, January 1, 201818315000008296000000
Tuesday, January 1, 201917733000007536000000
Wednesday, January 1, 202018152000007725000000
Friday, January 1, 202114162000007594000000
Saturday, January 1, 202214554000006973000000
Sunday, January 1, 202316804000007646000000
Monday, January 1, 20248064000000
Loading chart...

Igniting the spark of knowledge

Gross Profit Trends: Teva vs. Perrigo

In the competitive landscape of pharmaceuticals, understanding financial health is crucial. This analysis delves into the gross profit trends of Teva Pharmaceutical Industries Limited and Perrigo Company plc from 2014 to 2023. Over this period, Teva consistently outperformed Perrigo, with its gross profit peaking in 2016 at approximately 11.9 billion, a stark contrast to Perrigo's peak of around 2.1 billion in the same year. However, Teva's gross profit saw a decline of about 41% by 2022, reflecting industry challenges and strategic shifts. Meanwhile, Perrigo maintained a more stable trajectory, with fluctuations within a 20% range. This data highlights the dynamic nature of the pharmaceutical industry, where market forces and strategic decisions significantly impact financial outcomes. As we move forward, these insights provide a valuable lens through which to view the evolving strategies of these industry giants.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025